论文部分内容阅读
目的:分析比较茚达特罗与沙美特罗氟替卡松治疗激素耐药型慢性阻塞性肺部疾病的临床效果。方法:选择我院近年来收治的激素耐药型慢性阻塞性肺部疾病患者为本次研究对象,按照随机自愿的原则分为观察组和对照组,对照组给予沙美特罗氟替卡松,观察组给予马来酸茚达特罗。观察比较两组患者临床症状改善情况,并进行疗效评估。结果:观察组肺功能FEV1、IC及Pa O2指标均显著高于对照组(P<0.05);两组BODE指数及SGRO分数治疗后均出现显著降低(P<0.05),观察组治疗后BODE指数及SGRO分数均显著低于对照组(P<0.05)。结论:茚达特罗与沙美特罗氟替卡松治疗激素耐药型慢性阻塞性肺部疾病,能够明显改善和提高患者肺功能及预后效果,值得临床推广。
Objective: To compare and analyze the clinical effect of indacaterol and salmeterol fluticasone in the treatment of steroid-resistant chronic obstructive pulmonary disease. Methods: The patients with steroid-resistant chronic obstructive pulmonary disease who were treated in our hospital in recent years were selected as the study subjects and divided into observation group and control group according to the principle of randomness and voluntarily. The control group was given salmeterol fluticasone, and the observation group was given Indacaterol maleate. The clinical symptoms of two groups were observed and compared, and the curative effect was evaluated. Results: The indexes of FEV1, IC and Pa O2 in lung function of observation group were significantly higher than those of control group (P <0.05). The BODE index and SGRO score of the two groups were significantly decreased after treatment (P <0.05) And SGRO scores were significantly lower than the control group (P <0.05). CONCLUSION: Indacaterol and salmeterol / fluticasone are effective in treating steroid-resistant chronic obstructive pulmonary disease, which can significantly improve and enhance pulmonary function and prognosis in patients. It is worthy of clinical promotion.